Professional Documents
Culture Documents
Biopharmaceutic Considerations
Biopharmaceutics is the area of the study embracing the relationship between physical, chemical and biological sciences as they apply to drug and to drug action
ADME
Bioavailability - describe the rate and extent to which an active drug ingredient or therapeutic moiety is absorbed from a drug product and becomes available at the site of the drug action. Bioequivalence - refers to the comparison of bioavailabilities of different formulations, drug products, or batches of the same drug product.
Terms Used To define The Type or Level Of Equivalency Between Drug Products
Pharmaceutical Equivalents -are drug products that contain
amounts of the identical active ingredient. Example: the ester of the same therapeutic moiety identical same salt or
Therapeutic Equivalent - has been used to indicate pharmaceutical equivalent which, when administered to the same individuals in the same dosage regimens, will provide essentially the same therapeutic effect.
The most common experimental plan to compare the bioavailability of two drug products is the simple crossover design study. (12 to 14 individuals, males between 18 to 40 same height and weight) years,
How A Drug Passes Through The Body 1. Absorption = The site at which a drug enters the body affects its rates of absorption a. Skin b. Lungs c. Digestive Tract d. Bloodstream
2. Distribution = Most drugs enter the bloodstream; many are then distributed to cells of various organs a. Bone b. Nerves c. Muscles d. Brain e. Glands f. Heart g. Cells h. Other organs
3. Metabolism = A drug is partially broken down, usually in the liver, before or after distribution
a. Liver 4. Elimination = Finally, a drug is eliminated, mainly via kidneys, but also in stools and tears or through breathing a. Breast milk b. Saliva c. Tears d. Sweat
1. Contain the same active ingredients as the pioneer drug (inert ingredient may vary) 2. Be identical in strength, dosage form, and route of administration 3. Have the same indications and precautions for use and other labeling instructions 4. Be bioequivalent
5. Meet the same batch to batch requirements for identity, strength, purity, and quality
6. Be manufactured under the same strict standards of FDAs CGMP regulations as required for pioneer products.
Some Factors Which Can influence The Bioavailability Of Orally Administered Drugs
I. Drug Substance Physiochemical Properties II. Pharmaceutical Ingredients and Dosage Form Characteristics
Some Factors Which Can influence The Bioavailability Of Orally Administered Drugs
Some Factors Which Can influence The Bioavailability Of Orally Administered Drugs
II. Pharmaceutic Ingredients and Dosage Form Characteristics
A. Pharmaceutical Ingredients
1. Fillers 2. Binders 3. 4. 5. 6. Coatings Disintegrating Agents Lubricants Suspending Agents 7. Surface Active Agents 8. Flavoring Agents 9. Coloring Agents 10. Preservative Agents 11. Stabilizing Agents
Some Factors Which Can influence The Bioavailability Of Orally Administered Drugs
B. Disintegration Rate (Tablets) C. Dissolution Time of Drug in Dosage Form D. Product Age and storage Conditions
D. Gastric Contents
1. Food 2. Other Drugs 3. Fluid
E. Gastrointestinal pH
F. Drug Metabolism (gut and during first passage through liver)
Examples Of Drugs That Undergo Significant Liver Metabolism and Exhibit Low Bioavailability when Administered by First-pass Routes
Propoxyphene
Antianginal Antiarrhythmics Beta-adrenergic Nitroglycerin Lidocaine Labetolol, Metoprolol, Propranolol
blockers
Calcium channel blockers Sympathomimetic Isoproterenol Verapamil
amines
Tricyclic antidepressants Desipramine, Imipramine, Nortriptyline
Oxidation
(active)
3. Procainamide (active) 4. Nitroglycerin Hydrolysis
(inactive)
p-Aminobenzoic acid (inactive) reduction 1-2 and 1-3 dinitroglycerol
(active)
(inactive)
Some compound under full, partial no biotransformation 1. Lisinopril (zestril) - does not go metabolism, excreted unchanged
Routes Of Drug Administration TERM oral peroral (per os, p.o.) mouth gastrointestinal tract via mouth SITE
sublingual
parenteral intravenous intraarterial
intracardiac
intraspinal/intrathecal intraosseous intraarticular
heart
spine bone joint
intrasynovial
intracutaneous/intradermal subcutaneous intramuscular
joint-fluid area
skin beneath the skin muscle
TERM
SITE
epicutaneous (topical) transdermal conjunctival intraocular intranasal aural intrarespiratory rectal vaginal urethral
skin surface skin surface conjunctiva eye nose ear lung rectum vagina urethra
Route Of Administration
oral
sublingual parenteral
epicutaneous/transdermal
ointments, creams, infusion pumps pastes, plasters, powders, aerosols lotions, transdermal patches, discs
contact lens inserts, ointments solutions, suspensions solutions, sprays, inhalants, oint. aerosols
Route Of Administration
rectal
vaginal urethral
Activity, Toxicity
Minimum therapeutic dose Toxic Dose Therapeutic index
Pharmacoknetics
Absorption Distribution Metabolism
Dosage Regimen
Side effects
Dose-response relationship
Excretion
Other Factors
Management of Therapy
Convenience of regimen Pharmacogeneticsidiosyncrasy
Drug interactions